

RECEIVED  
CENTRAL FAX CENTER  
OCT 16 2006COLEMAN SUDOL SAPONE, P.C.  
714 COLORADO AVENUE  
BRIDGEPORT, CT 06605-1601  
FAX: (203) 335-6779/6899

## FACSIMILE TRANSMITTAL SHEET

TO:	FROM:
U.S. Patent and Trademark Office	Henry D. Coleman
U.S. PATENT APPLICATION NO.:	FILED:
10/646,980	08/22/2003
FAX NUMBER:	TOTAL NO. OF PAGES INCL. COVER
571-273-8300; 571-272-5548	2
DATE:	OUR REFERENCE NO.:
October 16, 2006	G25-078
RE:	
Please receive the Terminal Disclaimer submitted herewith in the above-identified patent application.	

Certificate of Facsimile Transmission Under 37 C.F.R. § 1.8

I hereby certify that this paper is being sent by facsimile transmission to the United States Patent and Trademark Office on the date shown below.



Harold Hull

Date: October 16, 2006

*PLEASE NOTE: The information contained in this facsimile message is privileged and confidential, and is intended only for the use of the individual named above and others specifically authorized to receive it. If you are not the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you received this communication in error, or if any problems occur with transmission, please notify us immediately by telephone at (203) 366-3560. Thank you.*

## UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED  
CENTRAL FAX CENTER

OCT 16 2006

APPLICANT(S) : Chu and Cheng  
SERIAL NO. : 10/646,980  
FILED : August 22, 2003  
FOR : Compounds and Methods for the Treatment of Cancer  
GROUP ART UNIT : 1616  
EXAMINER : J. H. Alstrum Acevedo

MailDrop: After Final  
United States Patent and Trademark Office  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

## Terminal Disclaimer

The owners\*, The University of Georgia Research Foundation, Inc. and Yale University, of 100 percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. 154 and 173, as presently shortened by any terminal disclaimer, of prior patent U.S. no. 5,817,667. The owners hereby agree that any patent so granted on the instant application shall be enforceable only for and during such period that it and the prior patent are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 and 173 of the prior patent, as presently shortened by any terminal disclaimer, in the event that it later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.

Check either box 1 or 2 below, if appropriate.

1. ☐ For submissions on behalf of an organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the organization.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

2. ☒ The undersigned is an attorney or agent of record.

Signature

Date

Type or Printed Name

Telephone Number

- ☒ Terminal disclaimer fee under 37 C.F.R. 1.20d(d) included.